ContraFect
28 Wells Avenue, Third Floor
Yonkers, NY 10701
United States
Tel: 914-207-2300
Website: http://www.contrafect.com/
About ContraFect
ContraFect, a late-stage clinical biotechnology company focused on the discovery and development of biotherapeutics for life-threatening, drug-resistant infectious diseases is located in Westchester County, near New York City. We are dedicated to innovative drug development, leveraging novel technologies to create new therapies that address the high unmet medical needs of patients suffering from serious, antibiotic-resistant infections for which there are limited available treatment options. We are using ContraFect’s technical expertise to develop biotherapeutics for serious bacterial infections, including those caused by MDR and XDR strains that have high unmet medical needs, particularly products used in hospital-based markets.
It is an exciting time in our Company’s history as we advance our direct lytic agent (DLA) platform of lysins and amurin peptides into the clinic. Exebacase (CF-301), our lead lysin, is the first and only direct lytic agent to report promising results in Phase 2 and to advance to Phase 3 of development. Earlier last year, the FDA granted Breakthrough Therapy designation to exebacase for development as a treatment for MRSA bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics. The exebacase Phase 3 study, known as the DISRUPT Study (“ Direct Lysis of Staph aureus Resistant Pathogen Trial”) ongoing in the United States and will serve as the single pivotal trial to support the BLA. ContraFect also has an active discovery pipeline of DLAs discovered at ContraFect which are progressing towards the clinic with support from major funding agencies including the Department of Defense, CARB-X and the Cystic Fibrosis Foundation. Our lead IND candidate, CF-370, a lysin targets MDR Pseudomonas aeruginosa, a bacteria identified as a serious threat in the CDC’s Antibiotic Threats in the US, 2019 report.
102 articles with ContraFect
-
ContraFect Announces Multiple Publications on Exebacase, Including First Manuscript on Local Administration of Lysin for Potential Treatment of Prosthetic Joint Infections
5/26/2021
Exebacase showed the potential to be used in patients with chronic Staphylococci prosthetic knee infection (PKI) to reduce symptoms and improve function The observed clinical responses in patients treated under compassionate use in France warrant further study of the use of intra-articular administration of exebacase for prosthetic joint infection (PJI)
-
ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office
5/3/2021
ContraFect Corporation, a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced that the United States Patent and Trademark Office issued U.S. Patent No. 10,988,520, on April 27, 2021 for CF-370, the company’s second potential therapeutic product candidate.
-
ContraFect Invited to Participate in the Cystic Fibrosis Target Product Profile Virtual Symposium
4/26/2021
ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research, will participate in the Cystic Fibrosis (CF) Target Product Profile Symposium
-
ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
3/30/2021
Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infections; results from interim futility analysis anticipated in H2 2021
-
ContraFect Corporation Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
3/22/2021
ContraFect Corporation announced the closing of an underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $5.00 per share, including 1,500,000 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares.
-
ContraFect Corporation Prices Public Offering of Common Stock - Mar 18, 2021
3/18/2021
ContraFect Corporation, a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share.
-
ContraFect Corporation Announces Proposed Public Offering of Common Stock - Mar 17, 2021
3/17/2021
ContraFect Corporation, a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, announced that it has commenced an underwritten public offering of shares of its common stock.
-
Investment dollars continue to flood the life sciences industry as new technologies and groundbreaking approaches tear down the dams that have previously hindered advancement.
-
ContraFect Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook
3/11/2021
BARDA to provide funding for the ongoing Phase 3 DISRUPT study of exebacase for the treatment of patients with Staph aureus bloodstream infections
-
ContraFect Announces Appointment of Dr. Jane F. Barlow to Board of Directors
2/11/2021
ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs) as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the appointment of Jane F. Barlow, MD, MPH, MBA to the Company’s board of directors (Board).
-
ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update
11/13/2020
ContraFect Corporation (Nasdaq: CFRX) a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the third quarter ended September 30, 2020.
-
ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients
10/26/2020
ContraFect Corporation announced that it has initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients.
-
ContraFect to Present at the 2020 Cantor Global Virtual Healthcare Conference
9/9/2020
ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Roger J. Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a Fireside Chat at the 2
-
ContraFect Announces Funding Agreement with the Cystic Fibrosis Foundation
8/25/2020
Initial evaluation of Direct Lytic Agents (DLAs) as potential novel modalities to address lung infections caused by antibiotic-resistant Gram-negative bacterial pathogens in Cystic Fibrosis
-
ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
8/14/2020
Exebacase Phase 2 study results published in the Journal of Clinical Investigation Continued patient enrollment in ongoing Phase 3 DISRUPT study of exebacase Successful public equity offering, private placement with Pfizer Inc., and CARB-X grant provide significant funding to advance lead product candidates YONKERS, New York, Aug. 14, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and develop
-
ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development
7/20/2020
ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator),
-
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
6/17/2020
Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia
-
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
6/15/2020
ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced the appointment of Lishan Aklog, M.D. to the Company’s board of directors.
-
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.
5/26/2020
ContraFect Corporation announced that Pfizer Inc. has entered into a stock purchase agreement with ContraFect pursuant to which Pfizer Inc. has agreed to purchase 674,156 shares of ContraFect’s common stock and a warrant to purchase 505,617 shares of ContraFect’s common stock, for approximately $3.0 million in a private placement transaction that is expected to close on May 27, 2020.
-
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants
5/22/2020
ContraFect Corporation announced the pricing of its underwritten public offering of 11,797,752 shares of its common stock and related warrants to purchase 8,848,314 shares of common stock with an exercise price of $4.90 per share, in exchange for consideration equating to $4.45 for one share of common stock and a warrant to purchase 0.75 shares of common stock.